Spun out of GigaGen - pre-clinical biotherapeutics company using microfluidics, bioinformatics, sequencing, and genetic engineering to mine B and T cell repertoires for full length natively paired antibodies and T cell receptors (TCRs) - GigaMune is structured to combine useful insight into T cell responses to tumors with a massively parallel T cell receptor (TCR) discovery to develop the next generation of T cell therapies. The firm's patented TCR technologies facilitate discovery of rare TCRs from the immune repertoires of patients with exceptional response to cancer. The companys research efforts benefit from a strategic partnership with Massachusetts General Hospital and Harvard Medical School.
